- Alpha Cognition Inc. (ACOG, Financial) successfully launched ZUNVEYL in the U.S. long-term care market on March 17, 2025.
- ZUNVEYL generated net product revenues of $0.35 million and licensing revenue of $2.6 million in Q1 2025.
- Medicare reimbursement was secured post-launch, enhancing patient access in long-term care settings.
Alpha Cognition Inc. (ACOG) announced the successful launch of its product, ZUNVEYL(R) (benzgalantamine), in the U.S. long-term care (LTC) market as of March 17, 2025. The launch has yielded positive early results, receiving strong feedback from both clinicians and patients, which has translated into successful patient outcomes and a robust ordering momentum in the market. ZUNVEYL's entry into the market was complemented by a swift Medicare reimbursement approval, significantly improving patient access in LTC environments.
Financially, Alpha Cognition reported ZUNVEYL's net product revenues at $0.35 million, alongside licensing revenue of $2.6 million, for the first quarter of 2025. The company also achieved a strategic milestone by securing a new composition of matter patent for the benzgalantamine tablet formulation in the U.S., which strengthens its intellectual property position. Management has confirmed that all launch objectives are on track and remain within budget, with commercial execution progressing according to plan.
